Calendar Decisions Readouts Run-up Stocks

Drug Index Conferences Advisory Committees Screener Research API SLS tracker Account

Home › Condition › Cancer & Oncology

Upcoming Cancer & Oncology FDA decisions & readouts

Updated August 7, 2026·next FDA decision on the calendar

PDUFA target dates and trial readouts in cancer & oncology, each linked to its primary source. Updated from FDA/SEC/ClinicalTrials.gov; dates can shift.

Obesity & Metabolic CNS & Neurology Immunology & Inflammation Cardiovascular Rare Disease Infectious Disease & Vaccines Hematology Ophthalmology & Eye

PDUFA decisions (13)

ARVN · 2026-06-05

ARV-471: Advanced Breast Cancer

ACHV · 2026-06-20

Custirsen: Non-Small Cell Lung Cancer

HOOK · 2026-08-17

Pembrolizumab combination: Oncology (Priority Review)

CRBP · 2026-08-17

Pembrolizumab combination: Oncology (Priority Review)

NCNA · 2026-08-17

Pembrolizumab combination: Oncology (Priority Review)

TLX · 2026-09-11

177Lu-TLX591: Metastatic Castration-resistant Prostate Cancer

NUVL · 2026-09-18

Neladalkib: Non-small Cell Lung Cancer

BAYRY · 2026-11-30

Sevabertinib (BAY 2927088): HER2-mutant NSCLC

RHHBY · 2026-12-18

Giredestrant: ER+/HER2- metastatic breast cancer

COGT · 2026-12-30

CGT9486: Advanced Gastrointestinal Stromal Tumors

CGEM · 2027-02-27

CLN-081: Non Small Cell Lung Cancer

INBX · 2027-04-14

INBRX-106: Head and Neck Squamous Cell Carcinoma (HNSCC)

Trial readouts (264)

LEGN · Jun 2026 (est.)

LCAR-B38M CAR-T Cell: B-Cell Non-Hodgkin Lymphoma-Recurrent

JAZZ · Jun 2026 (est.)

Zanidatamab: Gastroesophageal Adenocarcinoma

CLLS · Jun 2026 (est.)

UCART22: B-cell Acute Lymphoblastic Leukemia

CELC · Jun 2026 (est.)

Gedatolisib: Breast Cancer

BMY · Jun 2026 (est.)

Nivolumab: Metastatic Renal Cell Carcinoma

OLMA · Jun 2026 (est.)

Palazestrant: Breast Cancer

TLX · Jun 2026 (est.)

177Lu-TLX591: Clear Cell Renal Cell Carcinoma

JAZZ · Jul 2026 (est.)

Lurbinectedin: Advanced Soft-tissue Sarcoma

IOVA · Jul 2026 (est.)

Lifileucel plus Pembrolizumab: Soft Tissue Sarcoma

HOWL · Jul 2026 (est.)

WTX-330: Metastatic Solid Tumor

EXEL · Jul 2026 (est.)

Cabozantinib: Non-Small Cell Lung Cancer

ELVN · Jul 2026 (est.)

ELVN-002: HER2 Mutant Non-small Cell Lung Cancer

CRDF · Jul 2026 (est.)

Onvansertib: Pancreatic Cancer

SMMT · Jul 2026 (est.)

Ivonescimab: Salivary Gland Cancer

PYXS · Jul 2026 (est.)

PYX-201: Solid Tumor

CANF · Jul 2026 (est.)

Namodenoson: Pancreatic Adenocarcinoma

LTRN · Jul 2026 (est.)

Tavocept(BNP7787) in combination with cisplatin and either docetaxel or paclitaxel: Advanced Solid Tumor

JAZZ · Jul 2026 (est.)

Tislelizumab: Gastric Neoplasms

PSNL · Jul 2026 (est.)

Pembrolizumab: Adenocarcinoma of the Colon

KPTI · Aug 2026 (est.)

Selinexor: Endometrial Cancer

CADL · Aug 2026 (est.)

Aglatimagene Besadenovec: Prostate Cancer Patients Treated by Radiotherapy

CORT · Aug 2026 (est.)

Relacorilant: Ovarian Cancer

CRIS · Aug 2026 (est.)

chondrocyte-alginate gel suspension: Relapsed Hematologic Malignancy

NCNA · Aug 2026 (est.)

NUC-1031: Advanced Cancer

ACRV · Aug 2026 (est.)

ACR-368: Specific Advanced Solid Tumors

PMVP · Aug 2026 (est.)

rezatapopt: Advanced Solid Tumor

CLRB · Aug 2026 (est.)

NOV-002: Pediatric Solid Tumor

NRIX · Aug 2026 (est.)

NX-5948: Ovarian Cancer, Epithelial

ARVN · Sep 2026 (est.)

ARV-471: Breast Cancer

GILD · Sep 2026 (est.)

Sacituzumab Govitecan: Non-small Cell Lung Cancer

CGEM · Sep 2026 (est.)

CLN-081: Multiple Myeloma

LEGN · Sep 2026 (est.)

LCAR-B38M CAR-T Cell: Relapsed B-cell Non-Hodgkin Lymphoma

IOVA · Sep 2026 (est.)

Lifileucel plus Pembrolizumab: Gastric Cancer

TYRA · Sep 2026 (est.)

TYRA-300: Locally Advanced Cholangiocarcinoma

PCSA · Sep 2026 (est.)

PCS6422 and capecitabine: Breast Cancer

MRK · Sep 2026 (est.)

Pembrolizumab: Metastatic Triple-Negative Breast Cancer

NVCR · Sep 2026 (est.)

Temozolomide: Anaplastic (Malignant) Meningioma

ORIC · Sep 2026 (est.)

ORIC-114: Solid Tumors

BMY · Sep 2026 (est.)

Bevacizumab: Advanced Solid Tumors

IBRX · Sep 2026 (est.)

ALT-803: Non-muscle Invasive Bladder Cancer

EXEL · Sep 2026 (est.)

Cabozantinib: High Grade Neuroendocrine Neoplasms

CHRS · Sep 2026 (est.)

CHS-1420: Advanced Solid Tumor

CCCC · Sep 2026 (est.)

Cemsidomide: Multiple Myeloma

IMMP · Sep 2026 (est.)

eftilagimod alfa: Solid Tumors

PFE · Oct 2026 (est.)

Palbociclib: Metastatic Renal Cell Carcinoma

SNDX · Oct 2026 (est.)

Revumenib: Refractory Acute Myeloid Leukemia

AGEN · Oct 2026 (est.)

Balstilimab: Anatomic Stage IV Breast Cancer AJCC v8

IOVA · Oct 2026 (est.)

Lifileucel plus Pembrolizumab: HPV-Associated Cervical Carcinoma

PSTV · Oct 2026 (est.)

Rhenium Liposome Treatment: Leptomeningeal Metastasis

ADCT · Oct 2026 (est.)

Loncastuximab Tesirine: B-Cell Non-Hodgkin Lymphoma

MRK · Oct 2026 (est.)

Pembrolizumab: Metastatic Uveal Melanoma

INBX · Oct 2026 (est.)

INBRX-106: Solid Tumor

RCUS · Oct 2026 (est.)

Zimberelimab: Non Small Cell Lung Cancer

ADAG · Oct 2026 (est.)

Pembrolizumab: Advanced/Metastatic Solid Tumors

IMMP · Oct 2026 (est.)

eftilagimod alfa: Breast Carcinoma

ATOS · Nov 2026 (est.)

Z-Endoxifen: Breast Neoplasms

TLX · Nov 2026 (est.)

177Lu-TLX591: Prostate Adenocarcinoma

ERAS · Nov 2026 (est.)

Naporafenib: Advanced or Metastatic Solid Tumors

GILD · Nov 2026 (est.)

Sacituzumab Govitecan: Esophageal Squamous Cell Carcinoma

IOVA · Nov 2026 (est.)

Lifileucel plus Pembrolizumab: Metastatic Melanoma

ONC · Nov 2026 (est.)

BGB-11417: Relapsed/Refractory Multiple Myeloma

ANL · Nov 2026 (est.)

Buparlisib & Paclitaxel: Advanced Solid Tumor

TYRA · Nov 2026 (est.)

TYRA-300: Locally Advanced Urothelial Carcinoma

ELTX · Nov 2026 (est.)

ELI-002 7P: Pancreatic Ductal Adenocarcinoma

CRDF · Nov 2026 (est.)

Onvansertib: Metastatic Colorectal Cancer

BYSI · Nov 2026 (est.)

Docetaxel + Plinabulin: Multiple Myeloma

PGEN · Nov 2026 (est.)

PRGN-2009: Cervical Cancer

AURA · Nov 2026 (est.)

Bel-sar: Eye Cancer

EXEL · Dec 2026 (est.)

Cabozantinib: Metastatic Renal Cell Carcinoma

BEAM · Dec 2026 (est.)

BEAM-302: Lymphoblastic Lymphoma

BMY · Dec 2026 (est.)

Nivolumab: Non Small Cell Lung Cancer

CMPX · Dec 2026 (est.)

CTX-009: Biliary Tract Cancer

CNTX · Dec 2026 (est.)

Onapristone ER: Mesothelin-Expressing Tumors

DCTH · Dec 2026 (est.)

Cisplatin and Gemcitabine: Refractory Metastatic Colorectal Cancer

EIKN · Dec 2026 (est.)

EIK1001: Solid Tumor, Adult

AGEN · Dec 2026 (est.)

Balstilimab: Refractory Metastatic Colorectal Cancer

ADCT · Dec 2026 (est.)

Loncastuximab Tesirine: Diffuse Large B-Cell Lymphoma

MNPR · Dec 2026 (est.)

Clonidine HCl Mucoadhesive Buccal Tablet: Solid Tumor, Adult

MRK · Dec 2026 (est.)

Pembrolizumab: Squamous Cell Cancer of Head and Neck

ORIC · Dec 2026 (est.)

ORIC-114: Solid Tumors

PBYI · Dec 2026 (est.)

neratinib: Breast Cancer

PFE · Dec 2026 (est.)

Elranatamab: Multiple Myeloma

RCUS · Dec 2026 (est.)

Quemliclustat: Borderline Resectable Pancreatic Adenocarcinoma

GLSI · Dec 2026 (est.)

GLSI-100: Breast Cancer

GNLX · Dec 2026 (est.)

olvimulogene nanivacirepvec: SCLC, Extensive Stage

JAZZ · Dec 2026 (est.)

CPX-351: Acute Myeloid Leukemia (AML) in Remission

KPTI · Dec 2026 (est.)

Rituximab: Relapsed/Refractory Diffuse Large B-cell Lymphoma

KZIA · Dec 2026 (est.)

GDC-0084: Primary Central Nervous System Lymphoma

LTRN · Dec 2026 (est.)

Tavocept(BNP7787) in combination with cisplatin and either docetaxel or paclitaxel: Adenocarcinoma of Lung

SMMT · Dec 2026 (est.)

Ivonescimab: Stomach Cancer Stage IV

SNDX · Dec 2026 (est.)

Revumenib: Leukemia

ZNTL · Dec 2026 (est.)

Investigator's choice of Chemotherapy, High-Grade Serous Ovarian, Fallopian Tube or Primary Peritoneal Cancer

XNCR · Dec 2026 (est.)

XMAB20717: Biliary Tract Cancer

PFE · Dec 2026 (est.)

Mevrometostat: Metastatic Castration-Resistant Prostate Cancer

CRDF · Dec 2026 (est.)

Onvansertib: Breast Cancer

SNDX · Dec 2026 (est.)

Revumenib: Acute Myeloid Leukemia

ARVN · Dec 2026 (est.)

ARV-471: Breast Cancer

PBYI · Dec 2026 (est.)

neratinib: Lung Cancer Metastatic

PFE · Dec 2026 (est.)

Palbociclib: Breast Cancer

SYK · Dec 2026 (est.)

Ropivacaine: Sarcoma

ACTU · Dec 2026 (est.)

Losartan: Pancreatic Adenocarcinoma

ADAG · Dec 2026 (est.)

Pembrolizumab: Advanced Solid Tumor

ADCT · Dec 2026 (est.)

Loncastuximab Tesirine: Chronic Lymphocytic Leukemia

ARVN · Dec 2026 (est.)

ARV-471: Breast Cancer

JAZZ · Dec 2026 (est.)

Zanidatamab: Breast Cancer

BCAX · Dec 2026 (est.)

Ficerafusp alfa: Head and Neck Squamous Cell Carcinoma

CLDX · Dec 2026 (est.)

Barzolvolimab: Breast Cancer

ESLA · Dec 2026 (est.)

EB103: B-Cell Non-Hodgkin's Lymphoma (NHL)

EXEL · Dec 2026 (est.)

XL-092: Hepatocellular Carcinoma

TVRD · 2026-H1

TTI-101: Hepatocellular Carcinoma

CGON · 2026-H1

Cretostimogene Grenadenorepvec: Non Muscle Invasive Bladder Cancer

ZNTL · 2026-H2

Investigator's choice of Chemotherapy: Ovarian Cancer

AURA · 2026-H2

Bel-sar: Choroidal Melanoma

CGEM · Jan 2027 (est.)

CLN-081: Relapsed/Refractory Acute Myeloid Leukemia (AML)

ELVN · Jan 2027 (est.)

ELVN-002: HER2-positive Breast Cancer

EXEL · Jan 2027 (est.)

Cabozantinib: Germ Cell Tumor

INAB · Jan 2027 (est.)

Autologous genetically modified gamma-delta T cells: Acute Myeloid Leukemia

IOVA · Jan 2027 (est.)

Lifileucel plus Pembrolizumab: Cervical Cancer

KURA · Jan 2027 (est.)

Ziftomenib: Solid Tumors With HRAS Alterations

NRIX · Jan 2027 (est.)

NX-5948: Chronic Lymphocytic Leukemia (CLL)

NUVL · Jan 2027 (est.)

Neladalkib: Locally Advanced Solid Tumor

CADL · Jan 2027 (est.)

Aglatimagene Besadenovec: Malignant Glioma of Brain

BMY · Jan 2027 (est.)

Nivolumab: Hodgkin Lymphoma

REGN · Jan 2027 (est.)

Odronextamab: Follicular Lymphoma

GILD · Jan 2027 (est.)

MK-3475: Carcinoma, Non-Small-Cell Lung

IDYA · Jan 2027 (est.)

Darovasertib: Metastatic Uveal Melanoma

CRBP · Jan 2027 (est.)

CRB-701: Solid Tumor, Adult

SGMT · Jan 2027 (est.)

Denifanstat: Prostatic Neoplasms, Castration-Resistant

IDYA · Jan 2027 (est.)

IDE196: Metastatic Uveal Melanoma

APLM · Jan 2027 (est.)

Uproleselan: Metastatic Non Small Cell Lung Cancer

TVRD · Feb 2027 (est.)

TTI-101: Hepatocellular Carcinoma

SNDX · Feb 2027 (est.)

Revumenib: Acute Myeloid Leukemias

MRK · Feb 2027 (est.)

Pembrolizumab: Triple Negative Breast Cancer

GNLX · Feb 2027 (est.)

olvimulogene nanivacirepvec: Advanced Non-squamous Non-small-cell Lung Cancer

KRYS · Feb 2027 (est.)

KB803: Lung Cancer, Non-small Cell

NVCR · Feb 2027 (est.)

Temozolomide: Spinal Metastasis

AZN · Feb 2027 (est.)

R-Chop: Diffuse Large B-Cell Lymphoma

ADCT · Mar 2027 (est.)

Loncastuximab Tesirine: Relapsed or Refractory Large B-cell Lymphoma

NUVB · Mar 2027 (est.)

safusidenib: Advanced Solid Tumor

ONC · Mar 2027 (est.)

Zanubrutinib: Mantle Cell Lymphoma; Non-Hodgkin Lymphoma

URGN · Mar 2027 (est.)

UGN-104: Upper Urinary Tract Urothelial Carcinoma

VSTM · Mar 2027 (est.)

avutometinib: Mesonephric Gynecologic Cancer

AGIO · Mar 2027 (est.)

Mitapivat: Chondrosarcoma

ALLR · Mar 2027 (est.)

2X-121: Advanced Ovarian Cancer

AURA · Mar 2027 (est.)

Bel-sar: Non-muscle-invasive Bladder Cancer

IPHA · Mar 2027 (est.)

Monalizumab: Metastatic Cancer

BPTH · Mar 2027 (est.)

BP1001 in combination with Ventoclax plus decitabine: Acute Myeloid Leukemia, in Relapse

CGEN · Mar 2027 (est.)

COM701: Ovarian Cancer

COGT · Mar 2027 (est.)

CGT9486: Intrahepatic Cholangiocarcinoma (Icc)

SNDX · Mar 2027 (est.)

Revumenib: Acute Myeloid Leukemia

UTHR · Mar 2027 (est.)

CDX-1140: Ovarian Clear Cell Adenocarcinoma

GILD · Mar 2027 (est.)

Sacituzumab Govitecan: HER2-negative Breast Cancer

CGON · Mar 2027 (est.)

Cretostimogene Grenadenorepvec: High-Risk Non-Muscle-Invasive Bladder Cancer

TNGX · Mar 2027 (est.)

Abemaciclib: Non Small Cell Lung Cancer

KPTI · Apr 2027 (est.)

Selinexor: Multiple Myeloma

LONA · Apr 2027 (est.)

Lasofoxifene in combination with abemaciclib: Metastatic Breast Cancer

PBLS · Apr 2027 (est.)

FOG-001: Cancer

SMMT · Apr 2027 (est.)

Ivonescimab: Endometrial Cancer

VSTM · Apr 2027 (est.)

avutometinib: Low-Grade Serous Ovarian Cancer

CLDX · Apr 2027 (est.)

Barzolvolimab: Malignant Epithelial Neoplasms

IOVA · Apr 2027 (est.)

Lifileucel plus Pembrolizumab: Bone Sarcoma

IDYA · Apr 2027 (est.)

Darovasertib: Uveal Melanoma

REGN · Apr 2027 (est.)

Cemiplimab: Colon Cancer

AIM · Apr 2027 (est.)

Ampligen: Prostate Adenocarcinoma

TELO · May 2027 (est.)

Zn-Telomir: Triple-Negative Breast Cancer (TNBC)

TNGX · May 2027 (est.)

S095035: MTAP-deleted Solid Tumors

IOVA · May 2027 (est.)

Lifileucel plus Pembrolizumab: Uveal Melanoma

BOLT · May 2027 (est.)

BDC-4182: Gastric Cancer Adenocarcinoma Metastatic

CMPX · May 2027 (est.)

CTX-009: Metastatic Biliary Tract Cancer

REGN · May 2027 (est.)

Cemiplimab: Recurrent Ovarian Cancer

REGN · May 2027 (est.)

Cemiplimab: Non-Small Cell Lung Cancer

OLMA · May 2027 (est.)

Palazestrant: Advanced or Metastatic ER+ HER2- Breast Cancer (mBC)

ZLAB · May 2027 (est.)

ACRV · May 2027 (est.)

ACR-368: Endometrial Adenocarcinoma

RVMD · May 2027 (est.)

RMC-6236: Non-small Cell Lung Cancer (NSCLC)

BLLN · Jun 2027 (est.)

5-Fluorouracil: Gastroesophageal Adenocarcinoma

BSX · Jun 2027 (est.)

Colchicine: Hepatocellular Carcinoma

EIKN · Jun 2027 (est.)

EIK1001: Advanced Solid Tumor

VSTM · Jun 2027 (est.)

avutometinib: Pancreatic Ductal Adenocarcinoma (PDAC)

APRE · Jun 2027 (est.)

APR-246 + azacitidine: Advanced Solid Tumor

FTH · Jun 2027 (est.)

SNS-101: Solid Tumor, Adult

IMMP · Jun 2027 (est.)

eftilagimod alfa: Advanced/Metastatic Non-Small Cell Lung Cancer (NSCLC)

INBX · Jun 2027 (est.)

INBRX-106: Triple Negative Breast Cancer

IPHA · Jun 2027 (est.)

Monalizumab: Non Small Cell Lung Cancer

JAZZ · Jun 2027 (est.)

CPX-351: Acute Myeloid Leukemia

SMMT · Jun 2027 (est.)

Ivonescimab: Thymus Carcinoma

IMNN · Jun 2027 (est.)

IMNN-001: Ovarian Cancer

INDP · Jun 2027 (est.)

Decoy20: Solid Tumor, Adult

LEGN · Jun 2027 (est.)

LCAR-B38M CAR-T Cell: Relapsed/Refractory B-cell Malignancies

PBYI · Jun 2027 (est.)

neratinib: Hormone Receptor Positive HER-2 Negative Breast Cancer

ACRS · Jun 2027 (est.)

A-101: Metastatic Pancreatic Ductal Adenocarcinoma

BPTH · Jul 2027 (est.)

BP1001 in combination with Ventoclax plus decitabine: Solid Tumor, Adult

KPTI · Jul 2027 (est.)

Selinexor: Relapse Multiple Myeloma

KRYS · Jul 2027 (est.)

ANL · Jul 2027 (est.)

Buparlisib & Paclitaxel: Advanced Solid Tumor (Phase 1)

ONCY · Jul 2027 (est.)

REOLYSIN: Anal Cancer Metastatic

TPST · Jul 2027 (est.)

TPST-1120: Advanced Liver Cancers

MAIA · Jul 2027 (est.)

6-Thio-2'-Deoxyguanosine: Carcinoma, Non-Small -Cell Lung

SMMT · Aug 2027 (est.)

Ivonescimab: Advanced Head and Neck Squamous Cell Carcinoma

TLX · Aug 2027 (est.)

177Lu-TLX591: Clear Cell Renal Cell Carcinoma (ccRCC)

ZLAB · Aug 2027 (est.)

ZL-1310: Solid Tumors

ADCT · Aug 2027 (est.)

Loncastuximab Tesirine: Follicular Lymphoma

ASND · Aug 2027 (est.)

TransCon CNP: Advanced Solid Tumor

NVCR · Aug 2027 (est.)

Temozolomide: Adenocarcinoma of Lung

BBOT · Aug 2027 (est.)

BBO-11818: Non-Small Cell Lung Cancer

CLLS · Aug 2027 (est.)

UCART22: B-cell Non-Hodgkin Lymphoma (B-NHL)

JNJ · Aug 2027 (est.)

Talquetamab: Multiple Myeloma

SMMT · Aug 2027 (est.)

Ivonescimab: Biliary Tract Cancer

VIR · Aug 2027 (est.)

VIR-5818: Locally Advanced or Metastatic HER2-Expressing Cancers

VSTM · Aug 2027 (est.)

avutometinib: Thyroid Cancer

NVCR · Aug 2027 (est.)

Temozolomide: Pancreatic Adenocarcinoma

ONCY · Aug 2027 (est.)

REOLYSIN: Ras-mutated Metastatic Colorectal Cancer

CRDF · Aug 2027 (est.)

Onvansertib: Small-cell Lung Cancer

BNTX · Aug 2027 (est.)

ONC-392: Non Small Cell Lung Cancer

CHRS · Sep 2027 (est.)

CHS-1420: Hepatocellular Carcinoma

CORT · Sep 2027 (est.)

Relacorilant: Adenocarcinoma

IOVA · Sep 2027 (est.)

Lifileucel plus Pembrolizumab: Unresectable Melanoma

NEO · Sep 2027 (est.)

IO102-IO103 in combination with pembrolizumab, Locoregionally Advanced Head and Neck Squamous Cell Carcinoma (LA-HNSCC)

RZLT · Sep 2027 (est.)

Ersodetug: Tumor Hyperinsulinism (Tumor HI)

SMMT · Sep 2027 (est.)

Ivonescimab: Metastatic Esophageal Adenocarcinoma

TLSI · Sep 2027 (est.)

Pembrolizumab: Locally Advanced Pancreatic Adenocarcinoma

AGEN · Sep 2027 (est.)

Botensilimab: Metastatic Colorectal Cancer

ADPT · Sep 2027 (est.)

Bendamustine: Lymphoma

VIR · Sep 2027 (est.)

VIR-5500: Hormone-refractory Prostate Cancer

MAIA · Sep 2027 (est.)

6-Thio-2'-Deoxyguanosine: Carcinoma, Non-Small-Cell Lung

ACTU · Sep 2027 (est.)

ING-41: Pancreatic Adenocarcinoma

CORT · Oct 2027 (est.)

Relacorilant: Metastatic Breast Cancer

NVCR · Oct 2027 (est.)

Temozolomide: Pancreas Cancer

OGN · Oct 2027 (est.)

150μg CFA (Elonva®) at stimulation day (SD) 1 and 100μg CFA(Elonva®) at SD 5: Esophagogastric Adenocarcinoma

AGEN · Oct 2027 (est.)

Balstilimab: Metastatic Prostate Cancer

APVO · Oct 2027 (est.)

ALG.APV-527: Acute Myeloid Leukemia (AML)

ONC · Oct 2027 (est.)

Tislelizumab: Metastatic Gastric Adenocarcinoma

PBYI · Oct 2027 (est.)

neratinib: Small Cell Lung Cancer

TFX · Oct 2027 (est.)

Fresh Frozen Plasma: Cervix Cancer

TLX · Oct 2027 (est.)

177Lu-TLX591: Advanced Cancer

CUE · Oct 2027 (est.)

CUE-101: Oropharyngeal Squamous Cell Carcinoma

CHRS · Nov 2027 (est.)

CHS-1420: Ovarian Cancer Stage IV

CRIS · Nov 2027 (est.)

chondrocyte-alginate gel suspension: Chronic Lymphocytic Leukemia

CRVS · Nov 2027 (est.)

Soquelitinib: Peripheral T-Cell Lymphoma, Not Otherwise Specified

ONC · Nov 2027 (est.)

BGB-3111: B-cell Malignancies

SYK · Nov 2027 (est.)

Ropivacaine: Breast Cancer

AURA · Nov 2027 (est.)

Bel-sar: Choroidal Melanoma

CGEN · Nov 2027 (est.)

COM701: Neoplasm

MYGN · Nov 2027 (est.)

Niraparib: Solid Tumor

CTMX · Nov 2027 (est.)

CX-072: Solid Tumor, Adult

AKTS · Dec 2027 (est.)

AKY-1189: Urothelial Carcinoma Bladder

ALLO · Dec 2027 (est.)

Fludarabine: Large B-cell Lymphoma

ADAG · Dec 2027 (est.)

ADG106: HER2-negative Breast Cancer

VSTM · Dec 2027 (est.)

avutometinib: Endometrioid Cancer

TLX · Dec 2027 (est.)

177Lu-TLX591: Metastatic Castration-resistant Prostate Cancer

STRO · Dec 2027 (est.)

Luveltamab tazevibulin: Head and Neck Squamous Cell Carcinoma HNSCC

SMMT · Dec 2027 (est.)

Ivonescimab: Extensive Stage Lung Small Cell Cancer

RVMD · Dec 2027 (est.)

RMC-6236: NSCLC (Non-small Cell Lung Cancer)

RADX · Dec 2027 (est.)

RAD101: Castration-Resistant Prostate Cancer (CRPC)

BCTX · Dec 2027 (est.)

SV-BR-1-GM: Breast Cancer

BPTH · Dec 2027 (est.)

BP1001 in combination with Ventoclax plus decitabine: Acute Myeloid Leukemia (AML)

INTS · Dec 2027 (est.)

INT230-6: Sarcoma,Soft Tissue

KURA · Dec 2027 (est.)

Ziftomenib: Gastrointestinal Stromal Tumor (GIST)

LEGN · Dec 2027 (est.)

LCAR-B38M CAR-T Cell: Gastric Cancer

NUVL · Dec 2027 (est.)

Neladalkib: Locally Advanced Solid Tumor

RIGL · Dec 2027 (est.)

Fostamatinib Disodium: Pancreatic Ductal Adenocarcinoma (PDAC)

PYXS · Dec 2027 (est.)

PYX-201: Advanced Solid Tumors

SNDX · Dec 2027 (est.)

Revumenib: Acute Myeloid Leukemia

We don't show an approval percentage for these cancer & oncology catalysts. Here's why.